ReproCELL Inc. announces the launch of a newline of human iPSC derived Alzheimer’s disease model neural cells
Yokohama, Kanagawa, Japan – ReproCELL Inc. (ReproCELL, CEO: Chikafumi Yokoyama, Ph.D. JASDAQ: 4978) announced today that the company will launch a new line of human iPS cell derived Alzheimer’s disease model neural cells, “ReproNeuro Glu-AD” based on gene modification technology and iPS cell technology in November, 2013. ReproCELL launched the world’s first human iPS cell derived Alzheimer’s disease model neural cells, “ReproNeuro Ach-AD” in July 2012. The cells have been used by pharmaceutical companies and academic research institutes for Alzheimer’s disease research. Newly launched “ReproNeuro Glu-AD”(glutamatergic neuron) is different from “ReproNeuro Ach-AD”(cholinergic neuron) in terms of neural cell type and function.
It is known that the decrease in acetylcholine content in the brain and abnormality in the glutamatergic neuronal system are associated with the onset of Alzheimer’s disease. These two disease model neural cells, “ReproNeuro Glu-AD” and “ReproNeuro Ach-AD” can provide researchers with valuable tools for drug screening and discovery in the field of Alzheimer’s disease research.
“ReproNeuro Glu-AD” is suitable for mass production and is shipped frozen like our existing human iPSC derived product line, enabling delivery worldwide.
ReproCELL has a great interest in contributing to Alzheimer’s disease research and drug development through our Alzheimer’s disease model cells,“ReroNeuro Glu-AD”and “ReproNeuro Ach-AD”.
For more information, please click here.